ADVM Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced several virtual presentations of data from the company’s gene therapy programs in May 2020.

American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting 2020Abstracts are available online and presentations and posters can be accessed through ASGCT’s website on May 12, 2020 at www.asgct.org.

Abstract Title (Oral): ADVM-022 Intravitreal Gene Therapy for Neovascular AMD - Results from the Phase 1 OPTIC Study Session: AAV Vectors - Clinical Studies IIDate/Time: Wednesday, May 13, 2020, 4:00 - 4:15 pm EDTSpeaker: Szilárd Kiss, M.D., Director of Clinical Research in the Department of Ophthalmology at Weill Cornell Medical Group

Abstract Title (Poster): Proof-of-Concept Studies in Mongolian Gerbils Support Intravitreal Gene Replacement Therapy of Human L-Opsin for Blue Cone MonochromacySession: AAV Vectors - Preclinical and Proof-of-Concept StudiesDate/Time: Wednesday, May 13, 2020, 5:30 - 6:30 pm EDT

Abstract Title (Poster): Large Scale Suspension Production of AAV Capsid Variant Libraries from Stable Recombinant HEK293 Cell BanksSession: Vector and Cell Engineering, Production or ManufacturingDate/Time: Tuesday May 12, 2020, 5:30 - 6:30 pm EDT 

Association for Vision and Ophthalmology (ARVO)The ARVO 2020 Annual Meeting has been cancelled and video-recorded presentations will be available online on ARVOLearn beginning May 16, 2020. Additionally, abstracts will be published in the journal Investigative Ophthalmology & Vision Science (IOVS) no later than July 31, 2020.

Abstract Title: Intravitreal Delivery of AAV2.7m8. Ranibizumab Suppresses Exudative Lesions in the NHP Laser Induced Model of nAMD

Abstract Title: Mouse Studies Support Intravitreal Gene Therapy for Blue Cone Monochromacy

About Adverum BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.

Investor and Media Inquiries:

Investors:Myesha LacyAdverum Biotechnologies, Inc.mlacy@adverum.com1-650-649-1257

Media:Cherilyn Cecchini, M.D.LifeSci Communicationsccecchini@lifescicomms.com1-646-876-5196